Chemistry & pharmacokinetics
Amycretin is a large peptide, roughly 68 amino acids, because it fuses two agonist regions into one chain. A fatty-acid…
A 68-amino-acid fusion, engineered to last
Amycretin is a large peptide, roughly 68 amino acids, because it fuses two agonist regions into one chain. A fatty-acid tail lets it cling to blood albumin, and stabilizing tweaks keep it from being destroyed by enzymes, so it can be dosed weekly by injection or daily as a pill.
This unit opens up that molecular design and follows the drug through the body: how it is built, why it lasts, and why both formulations climb the dose slowly.
Key terms
The molecule, module by module
Amycretin is a 68-amino-acid peptide (about 7847 daltons) with several functional modules: a GLP-1-active region, an amylin-active region, a short linker joining them, a fatty-acid tail for albumin binding, and stabilizing tweaks. Tap each module to see its job.
The design borrows the same albumin-binding trick as semaglutide (which uses a C18 diacid) and cagrilintide (a C20 diacid). Fusing two agonist regions is why amycretin is roughly twice the length of native amylin or GLP-1. The modular picture makes the engineering legible: two arms, one linker, a tail to last, and tweaks to survive.
AdvancedWhy albumin binding extends the half-life
Small peptides are cleared fast by the kidney and chewed up by enzymes. By clinging to albumin, the most abundant blood protein, amycretin becomes a large, protected complex that the kidney does not filter easily and enzymes cannot readily reach. It rides in the bloodstream as a slow-release depot, releasing free peptide gradually. This is the main reason a peptide can be dosed weekly instead of daily.